Azitra, Inc. Addresses False Report Regarding Sale of Securities
Rhea-AI Summary
Azitra (NYSE American: AZTR) on Nov. 7, 2025 denied a circulated report that it had priced a $44 million registered direct offering. The company said the report is false and urged investors to rely only on information issued through its official channels. Azitra also said it is taking steps to identify the source of the false report.
Positive
- Company publicly denied the $44 million registered direct offering claim on Nov. 7, 2025
- Company urged stakeholders to rely only on official channels for verified information
Negative
- A false report circulated claiming a $44 million registered direct offering
- Company must identify the source of the false report, creating potential market confusion
News Market Reaction 4 Alerts
On the day this news was published, AZTR declined 10.23%, reflecting a significant negative market reaction. Argus tracked a trough of -10.3% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $269K from the company's valuation, bringing the market cap to $2M at that time.
Data tracked by StockTitan Argus on the day of publication.
Azitra urges investors, stakeholders, and the public to rely only on information formally issued by the Company through its official channels. The Company is taking steps to identify the source of the false report.
About Azitra
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. Azitra is also progressing ATR-01, a preclinical program targeting ichthyosis vulgaris, with the goal of submitting an IND submission in 2026. The ATR-12, ATR-04 and ATR-01 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-addresses-false-report-regarding-sale-of-securities-302608182.html
SOURCE Azitra, Inc.
FAQ
Did Azitra (AZTR) price a $44 million registered direct offering on Nov. 7, 2025?
What should investors do after the false Azitra (AZTR) offering report?
How is Azitra (AZTR) responding to the false offering report dated Nov. 7, 2025?
Could the false $44 million offering report affect Azitra (AZTR) stock volatility?
Where can investors find verified Azitra (AZTR) announcements about offerings or financings?
